DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS 28
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
03-01-2018
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
DROSPIRENONE; ETHINYL ESTRADIOL
Tilgængelig fra:
MYLAN PHARMACEUTICALS ULC
ATC-kode:
G03AA12
INN (International Name):
DROSPIRENONE AND ESTROGEN
Dosering:
3MG; 0.03MG
Lægemiddelform:
TABLET
Sammensætning:
DROSPIRENONE 3MG; ETHINYL ESTRADIOL 0.03MG
Indgivelsesvej:
ORAL
Enheder i pakken:
28
Recept type:
Prescription
Terapeutisk område:
CONTRACEPTIVES
Produkt oversigt:
Active ingredient group (AIG) number: 0250430001; AHFS:
Autorisation status:
APPROVED
Autorisation dato:
2018-01-04
Produktets egenskaber
_Drospirenone and Ethinyl Estradiol Tablets 21 / 28 Product Monograph
_
_ _
Page 1 of 66
PRODUCT MONOGRAPH
PR
DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS 21
PR
DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS 28
3 mg drospirenone and 0.03 mg ethinyl estradiol tablets
In-house standard
Oral Contraceptive
Acne Therapy
Mylan Pharmaceuticals ULC Date of Preparation:
85 Advance Road January 03, 2018
Etobicoke, ON
M8Z 2S6
Submission Control No.: 211719
_Drospirenone and Ethinyl Estradiol Tablets 21 / 28 Product Monograph
_
_ _
Page 2 of 66
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT
INFORMATION................................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
3
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
15
DRUG INTERACTIONS
.........................................................................................................
19
DOSAGE AND ADMINISTRATION
.....................................................................................
27
OVERDOSAGE
........................................................................................................................
30
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
30
STORAGE AND STABILITY
.................................................................................................
35
SPECIAL HANDLING INSTRUCTIONS
...............................................................................
35
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 35
P
Læs hele dokumentet
